William Blair Weighs in on argenx SE’s Q1 2024 Earnings (NASDAQ:ARGX)

argenx SE (NASDAQ:ARGXFree Report) – Analysts at William Blair upped their Q1 2024 earnings estimates for shares of argenx in a note issued to investors on Wednesday, April 17th. William Blair analyst M. Minter now expects that the company will earn ($0.89) per share for the quarter, up from their previous estimate of ($1.24). The consensus estimate for argenx’s current full-year earnings is ($2.10) per share. William Blair also issued estimates for argenx’s FY2024 earnings at ($2.96) EPS and FY2025 earnings at $2.78 EPS.

argenx (NASDAQ:ARGXGet Free Report) last posted its quarterly earnings data on Thursday, February 29th. The company reported ($1.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.45). The company had revenue of $417.84 million during the quarter, compared to the consensus estimate of $378.60 million. argenx had a negative net margin of 23.26% and a negative return on equity of 16.97%. During the same quarter last year, the business earned ($0.70) earnings per share.

ARGX has been the subject of a number of other reports. Wedbush restated an “outperform” rating and set a $521.00 target price on shares of argenx in a report on Thursday. Wolfe Research began coverage on shares of argenx in a research note on Thursday, February 15th. They issued a “peer perform” rating for the company. Piper Sandler raised their price objective on shares of argenx from $518.00 to $522.00 and gave the stock an “overweight” rating in a research note on Friday, January 26th. Robert W. Baird decreased their price objective on shares of argenx from $505.00 to $490.00 and set an “outperform” rating for the company in a research note on Friday, March 1st. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $471.00 price objective on shares of argenx in a research note on Friday, March 22nd. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $528.16.

View Our Latest Report on ARGX

argenx Stock Performance

Shares of NASDAQ:ARGX opened at $360.23 on Friday. The stock has a market capitalization of $21.36 billion, a price-to-earnings ratio of -70.08 and a beta of 0.65. argenx has a 1-year low of $327.73 and a 1-year high of $550.76. The company has a 50 day moving average price of $387.43 and a 200 day moving average price of $420.57.

Institutional Investors Weigh In On argenx

Institutional investors and hedge funds have recently modified their holdings of the business. Raymond James Financial Services Advisors Inc. lifted its stake in shares of argenx by 30.4% in the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 14,470 shares of the company’s stock valued at $5,505,000 after purchasing an additional 3,374 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in argenx by 388.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,719 shares of the company’s stock worth $1,415,000 after acquiring an additional 2,958 shares during the period. RTW Investments LP raised its holdings in argenx by 5.2% in the 3rd quarter. RTW Investments LP now owns 507,195 shares of the company’s stock worth $249,352,000 after acquiring an additional 25,000 shares during the period. Townsquare Capital LLC raised its holdings in argenx by 96.6% in the 3rd quarter. Townsquare Capital LLC now owns 3,442 shares of the company’s stock worth $1,692,000 after acquiring an additional 1,691 shares during the period. Finally, Northern Trust Corp raised its holdings in argenx by 41.1% in the 3rd quarter. Northern Trust Corp now owns 39,936 shares of the company’s stock worth $19,634,000 after acquiring an additional 11,627 shares during the period. Institutional investors and hedge funds own 60.32% of the company’s stock.

About argenx

(Get Free Report)

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.

Featured Articles

Earnings History and Estimates for argenx (NASDAQ:ARGX)

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.